New developments in the management of head and neck cancer – impact of pembrolizumab

References

• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20151365E359E38625220842
   PubMed Web of Science ®Google Scholar
• MaaslandDHEvan den BrandtPAKremerBGoldbohmRASchoutenLJAlcohol consumption, cigarette smoking and the risk of subtypes of head-neck cancer: results from the Netherlands Cohort StudyBMC Cancer20141418724629046
   PubMed Web of Science ®Google Scholar
• D’SouzaGKreimerARViscidiRCase-control study of human papillomavirus and oropharyngeal cancerN Engl J Med2007356191944195617494927
   PubMed Web of Science ®Google Scholar
• SzturzPVermorkenJBImmunotherapy in head and neck cancer: aiming at EXTREME precisionBMC Med201715111028571578
   PubMed Web of Science ®Google Scholar
• ArgirisAHarringtonKJTaharaMEvidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neckFront Oncol201777228536670
   PubMed Web of Science ®Google Scholar
• VermorkenJBMesiaRRiveraFPlatinum-based chemotherapy plus cetuximab in head and neck cancerN Engl J Med2008359111116112718784101
   PubMed Web of Science ®Google Scholar
• EcharriMJLopez-MartinAHittRTargeted therapy in locally advanced and recurrent/metastatic head and neck squamous cell carcinoma (LA-R/M HNSCC)Cancers (Basel)201683E726742076
   PubMed Web of Science ®Google Scholar
• FDA Approves Pembrolizumab for Head and Neck CancerNational Cancer Institute Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2016/fda-pembrolizumab-hnsccAccessed September 11, 2017
   Google Scholar
• Research C for DE and Approved Drugs – Nivolumab for SCCHN Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm528920.htmAccessed September 11, 2017
   Google Scholar
• SimardEPTorreLAJemalAInternational trends in head and neck cancer incidence rates: differences by country, sex and anatomic siteOral Oncol201450538740324530208
   PubMed Web of Science ®Google Scholar
• CohenEEWLaMonteSJErbNLAmerican cancer society head and neck cancer survivorship care guidelineCA Cancer J Clin201666320323927002678
   PubMed Web of Science ®Google Scholar
• FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer2010127122893291721351269
   PubMed Web of Science ®Google Scholar
• RettigEMD’SouzaGEpidemiology of head and neck cancerSurg Oncol Clin N Am201524337939625979389
   PubMed Web of Science ®Google Scholar
• HashibeMBrennanPBenhamouSAlcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology ConsortiumJ Natl Cancer Inst2007991077778917505073
   PubMed Web of Science ®Google Scholar
• VineisPAlavanjaMBufflerPTobacco and cancer: recent epidemiological evidenceJ Natl Cancer Inst20049629910614734699
   PubMedGoogle Scholar
• MarronMBoffettaPZhangZFCessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer riskInt J Epidemiol201039118219619805488
   PubMed Web of Science ®Google Scholar
• KawakitaDHosonoSItoHImpact of smoking status on clinical outcome in oral cavity cancer patientsOral Oncol201248218619121996543
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive genomic characterization of head and neck squamous cell carcinomasNature2015517753657658225631445
   PubMed Web of Science ®Google Scholar
• BrugereJGuenelPLeclercARodriguezJDifferential effects of tobacco and alcohol in cancer of the larynx, pharynx, and mouthCancer19865723913953942973
   PubMed Web of Science ®Google Scholar
• BlotWJMcLaughlinJKWinnDMSmoking and drinking in relation to oral and pharyngeal cancerCancer Res19884811328232873365707
   PubMed Web of Science ®Google Scholar
• MehannaHMRattayTSmithJMcConkeyCCTreatment and follow-up of oral dysplasia – a systematic review and meta-analysisHead Neck200931121600160919455705
   PubMed Web of Science ®Google Scholar
• ShawRBeasleyNAetiology and risk factors for head and neck cancer: United Kingdom National Multidisciplinary GuidelinesJ Laryngol Otol2016130Suppl 2S9S1227841107
   PubMed Web of Science ®Google Scholar
• MarurSD’SouzaGWestraWHForastiereAAHPV-associated head and neck cancer: a virus-related cancer epidemicLancet Oncol201011878178920451455
   PubMed Web of Science ®Google Scholar
• GillisonMLAlemanyLSnijdersPJFHuman papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosisVaccine201230Suppl 5F34F5423199965
   PubMed Web of Science ®Google Scholar
• KreimerARJohanssonMWaterboerTEvaluation of human papillomavirus antibodies and risk of subsequent head and neck cancerJ Clin Oncol Off J Am Soc Clin Oncol2013312127082715
   PubMed Web of Science ®Google Scholar
• ChaturvediAKEngelsEAPfeifferRMHuman papillomavirus and rising oropharyngeal cancer incidence in the United StatesJ Clin Oncol Off J Am Soc Clin Oncol2011293242944301
   PubMed Web of Science ®Google Scholar
• MehannaHBeechTNicholsonTPrevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and regionHead Neck201335574775522267298
   PubMed Web of Science ®Google Scholar
• ChaturvediAKAndersonWFLortet-TieulentJWorldwide trends in incidence rates for oral cavity and oropharyngeal cancersJ Clin Oncol201331364550455924248688
   PubMed Web of Science ®Google Scholar
• KussIHathawayBFerrisRLGoodingWWhitesideTLDecreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neckClin Cancer Res200410113755376215173082
   PubMed Web of Science ®Google Scholar
• DasguptaSBhattacharya-ChatterjeeMO’MalleyBWChatterjeeSKInhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancerJ Immunol200517585541555016210663
   PubMed Web of Science ®Google Scholar
• FerrisRLProgress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed?ORL J Otorhinolaryngol Relat Spec200466633234015668533
   PubMed Web of Science ®Google Scholar
• KammertoensTSchülerTBlankensteinTImmunotherapy: target the stroma to hit the tumorTrends Mol Med200511522523115882610
   PubMed Web of Science ®Google Scholar
• Gildener-LeapmanNFerrisRLBaumanJEPromising systemic immunotherapies in head and neck squamous cell carcinomaOral Oncol201349121089109624126223
   PubMed Web of Science ®Google Scholar
• HeJHuYHuMLiBDevelopment of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancerSci Rep201551311026279307
   PubMed Web of Science ®Google Scholar
• TopalianSLDrakeCGPardollDMImmune checkpoint blockade: a common denominator approach to cancer therapyCancer Cell201527445046125858804
   PubMed Web of Science ®Google Scholar
• SharmaPHu-LieskovanSWargoJARibasAPrimary, adaptive, and acquired resistance to cancer immunotherapyCell2017168470772328187290
   PubMed Web of Science ®Google Scholar
• FerrisRLImmunology and immunotherapy of head and neck cancerJ Clin Oncol201533293293330426351330
   PubMed Web of Science ®Google Scholar
• Lyford-PikeSPengSYoungGDEvidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinomaCancer Res20137361733174123288508
   PubMed Web of Science ®Google Scholar
• AhamadiMFreshwaterTProhnMModel-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumorsCPT Pharmacometrics Syst Pharmacol201761495727863186
   PubMedGoogle Scholar
• MahmoodIPharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimationJ Pharm Sci200998103850386119177515
   PubMed Web of Science ®Google Scholar
• Elassaiss-SchaapJRossenuSLindauerAUsing model-based “learn and confirm” to reveal the pharmacokinetics-pharmacodynamics relationship of pembrolizumab in the KEYNOTE-001 trialCPT Pharmacomet Syst Pharmacol2017612128
   PubMedGoogle Scholar
• RobertCRibasAWolchokJDAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialLancet201438499481109111725034862
   PubMed Web of Science ®Google Scholar
• RibasAPuzanovIDummerRPembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialLancet Oncol201516890891826115796
   PubMed Web of Science ®Google Scholar
• SeiwertTYBurtnessBMehraRSafety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialLancet Oncol201617795696527247226
   PubMed Web of Science ®Google Scholar
• ChowLQMHaddadRGuptaSAntitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the Phase Ib KEYNOTE-012 expansion cohortJ Clin Oncol201634323838384527646946
   PubMed Web of Science ®Google Scholar
• BaumlJSeiwertTYPfisterDGPembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJ Clin Oncol201735141542154928328302
   PubMed Web of Science ®Google Scholar
• ESMO 2017 Press Release: KEYNOTE-040 Evaluates Pembrolizumab in Head and Neck Cancer|ESMO Available from: http://www.esmo.org/Press-Office/Press-Releases/KEYNOTE-040-Evaluates-Pembrolizumab-in-Head-and-Neck-CancerAccessed December 23, 2017
   Google Scholar
• FerrisRLBlumenscheinGJrFayetteJNivolumab for recurrent squamous-cell carcinoma of the head and neckN Engl J Med2016375191856186727718784
   PubMed Web of Science ®Google Scholar
• SegalNHOuSIBalmanoukianASUpdated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCC… | Oncology-PRO Available from: http://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/Updated-safety-and-efficacy-of-durvalumab-MEDI4736-an-anti-PD-L-1-antibody-in-patients-from-a-squamous-cell-carcinoma-of-the-head-and-neck-SCCHN-expansion-cohortAccessed September 12, 2017
   Google Scholar
• SchadendorfDDummerRHauschildAHealth-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanomaEur J Cancer201667465427596353
   PubMed Web of Science ®Google Scholar
• BrahmerJRRodríguez-AbreuDRobinsonAGPL04a.01: health-related quality of life for pembrolizumab vs chemotherapy in advanced NSCLC with PD-L1 TPS ≥50%: data from KEYNOTE-024J Thorac Oncol2017121S8S9
   Web of Science ®Google Scholar
• VaughnDJBellmuntJDe WitRHealth-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancerJ Clin Oncol2017356 Suppl Abstract 282
   Web of Science ®Google Scholar
• YearleyJHGibsonCYuNPD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancerClin Cancer Res201723123158316728619999
   PubMed Web of Science ®Google Scholar
• TopalianSLTaubeJMAndersRAPardollDMMechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapyNat Rev Cancer201616527528727079802
   PubMed Web of Science ®Google Scholar
• LeDTDurhamJNSmithKNMismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience2017357634940941328596308
   PubMed Web of Science ®Google Scholar
• DiazLAMarabelleADelordJPPembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRCJ Clin Oncol20173515 Suppl3071
   Web of Science ®Google Scholar
• FieldJKKiarisHHowardPVaughanEDSpandidosDAJonesASMicrosatellite instability in squamous cell carcinoma of the head and neckBr J Cancer1995715106510697734301
   PubMed Web of Science ®Google Scholar
• ChowLQMMehraRHaddadRIBiomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)J Clin Oncol20163415 Suppl6010
   Web of Science ®Google Scholar
• ZolkindPUppaluriRCheckpoint immunotherapy in head and neck cancersCancer Metastasis Rev201736347548928836124
   PubMed Web of Science ®Google Scholar
• HaddadRISeiwertTYChowLQMGenomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC)J Clin Oncol2017 Abstract 6009
   Web of Science ®Google Scholar